An update on the toxicity of Aβ in Alzheimer’s disease

Alzheimer's disease is characterized histopathologically by deposition of insoluble forms of the peptide Abeta and the protein tau in brain. Abeta is the principal component of amyloid plaques and tau of neurofibrillary tangles. Familial cases of AD are associated with causal mutations in the gene encoding the amyloid precursor protein, APP, from which the amyloidogenic Abeta peptide is derived, and this supports a role for Abeta in disease. Abeta can promote tau pathology and at the same time its toxicity is also tau-dependent. Abeta can adopt different conformations including soluble oligomers and insoluble fibrillar species present in plaques. We discuss which of these conformations exert toxicity, highlight molecular pathways involved and discuss what has been learned by applying functional genomics.

[1]  Jürgen Götz,et al.  Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia , 2008, Proceedings of the National Academy of Sciences.

[2]  M. Fändrich,et al.  Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial function in P301L tau transgenic mice , 2008, Journal of Molecular Medicine.

[3]  J. Götz,et al.  Divergent phosphorylation pattern of tau in P301L tau transgenic mice , 2008, The European journal of neuroscience.

[4]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[5]  J. Götz,et al.  Human but not rat amylin shares neurotoxic properties with Aβ42 in long‐term hippocampal and cortical cultures , 2008, FEBS letters.

[6]  J. Götz,et al.  Soluble Beta-Amyloid Leads to Mitochondrial Defects in Amyloid Precursor Protein and Tau Transgenic Mice , 2008, Neurodegenerative Diseases.

[7]  R. Cappai,et al.  Delineating the Mechanism of Alzheimer’s Disease Aβ Peptide Neurotoxicity , 2008, Neurochemical Research.

[8]  C. Sachse,et al.  Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Aβ protofibrils , 2007, Proceedings of the National Academy of Sciences.

[9]  M. Staufenbiel,et al.  Induction of Tau Pathology by Intracerebral Infusion of Amyloid-β-Containing Brain Extract and by Amyloid-β Deposition in APP × Tau Transgenic Mice , 2007 .

[10]  R. Araya,et al.  Treatment and prevention of mental disorders in low-income and middle-income countries , 2007, The Lancet.

[11]  A. Papassotiropoulos,et al.  Aβ treatment and P301L tau expression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re‐entry , 2007, The European journal of neuroscience.

[12]  Chunyu Wang,et al.  Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation , 2007 .

[13]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[14]  W. Klein,et al.  Aβ Oligomers Induce Neuronal Oxidative Stress through an N-Methyl-D-aspartate Receptor-dependent Mechanism That Is Blocked by the Alzheimer Drug Memantine* , 2007, Journal of Biological Chemistry.

[15]  R. Kayed,et al.  Small Molecule Inhibitors of Aggregation Indicate That Amyloid β Oligomerization and Fibrillization Pathways Are Independent and Distinct* , 2007, Journal of Biological Chemistry.

[16]  G. Belfort,et al.  Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. , 2007, Biochemistry.

[17]  C. Masters,et al.  Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. , 2007, Biochemistry.

[18]  N. Cairns,et al.  TDP‐43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations , 2007, Journal of neuropathology and experimental neurology.

[19]  T. Lehtimäki,et al.  Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration , 2007, Acta Neuropathologica.

[20]  Jürgen Götz,et al.  A Decade of Tau Transgenic Animal Models and Beyond , 2007, Brain pathology.

[21]  Jürgen Götz,et al.  β‐Amyloid treatment of two complementary P301L tau‐expressing Alzheimer's disease models reveals similar deregulated cellular processes , 2006, Proteomics.

[22]  Bruce L. Miller,et al.  Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.

[23]  D. Galati,et al.  Accumulation of Amyloid Precursor Protein in the Mitochondrial Import Channels of Human Alzheimer’s Disease Brain Is Associated with Mitochondrial Dysfunction , 2006, The Journal of Neuroscience.

[24]  C. Duijn,et al.  Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 , 2006, Nature.

[25]  S. Melquist,et al.  Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 , 2006, Nature.

[26]  Angus C. Nairn,et al.  Synaptic plasticity: one STEP at a time , 2006, Trends in Neurosciences.

[27]  J. Götz,et al.  Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? , 2006, Journal of neurochemistry.

[28]  E. Coulson,et al.  Does the p75 neurotrophin receptor mediate Aβ‐induced toxicity in Alzheimer's disease? , 2006, Journal of neurochemistry.

[29]  Amedeo Caflisch,et al.  Interpreting the aggregation kinetics of amyloid peptides. , 2006, Journal of molecular biology.

[30]  R. Kayed,et al.  ERK1/2 Activation Mediates Aβ Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures* , 2006, Journal of Biological Chemistry.

[31]  R. Nitsch,et al.  Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice , 2006, Genes, brain, and behavior.

[32]  J. Quinn,et al.  Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. , 2006, Human molecular genetics.

[33]  F. Chen,et al.  Active immunization trial in Aβ42-injected P301L tau transgenic mice , 2006, Neurobiology of Disease.

[34]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[35]  C. Masters,et al.  Amyloid-β Peptide Disruption of Lipid Membranes and the Effect of Metal Ions , 2006 .

[36]  L. Pennanen,et al.  Different tau epitopes define Aβ42-mediated tau insolubility , 2005 .

[37]  X. Chen,et al.  Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease , 2005 .

[38]  P. Keller,et al.  Globular amyloid β‐peptide1−42 oligomer − a homogenous and stable neuropathological protein in Alzheimer's disease , 2005 .

[39]  M. Rowan,et al.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. , 2005, Biochemical Society transactions.

[40]  M. Fändrich,et al.  The aggregation kinetics of Alzheimer's β‐amyloid peptide is controlled by stochastic nucleation , 2005, Protein science : a publication of the Protein Society.

[41]  R. Ravid,et al.  Proteomic and Functional Analyses Reveal a Mitochondrial Dysfunction in P301L Tau Transgenic Mice* , 2005, Journal of Biological Chemistry.

[42]  J. Götz,et al.  Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology , 2005, Progress in Neurobiology.

[43]  Jürgen Götz,et al.  Functional Genomics meets neurodegenerative disorders Part II: Application and data integration , 2005, Progress in Neurobiology.

[44]  Ian Parker,et al.  Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers*♦ , 2005, Journal of Biological Chemistry.

[45]  W. K. Cullen,et al.  Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo , 2005, Nature Medicine.

[46]  C. Barrow,et al.  Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. , 2005, Biophysical journal.

[47]  Xi Chen,et al.  ABAD enhances Aβ‐induced cell stress via mitochondrial dysfunction , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  Jill A. White,et al.  Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.

[49]  C. Masters,et al.  Copper-Dependent Inhibition of Human Cytochrome c Oxidase by a Dimeric Conformer of Amyloid-β1-42 , 2005, The Journal of Neuroscience.

[50]  M. Duchen,et al.  Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. , 2004, Biochimica et biophysica acta.

[51]  P. Day,et al.  Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. , 2004, Analytical biochemistry.

[52]  C. Haass,et al.  Amyloid β-induced Changes in Nitric Oxide Production and Mitochondrial Activity Lead to Apoptosis* , 2004, Journal of Biological Chemistry.

[53]  J. Götz,et al.  Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models , 2004, International Journal of Developmental Neuroscience.

[54]  Xi Chen,et al.  RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice , 2004, The EMBO journal.

[55]  T. Bayer,et al.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. , 2004, The American journal of pathology.

[56]  Peter J. Lenting,et al.  LRP/Amyloid β-Peptide Interaction Mediates Differential Brain Efflux of Aβ Isoforms , 2004, Neuron.

[57]  Feng Chen,et al.  Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals. , 2004, Current drug targets.

[58]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[59]  E. Rogaev,et al.  Role for glyoxalase I in Alzheimer's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[61]  Xi Chen,et al.  Materials and Methods Som Text Figs. S1 and S2 Table S1 References Abad Directly Links A␤ to Mitochondrial Toxicity in Alzheimer's Disease , 2022 .

[62]  R. Nitsch,et al.  Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice , 2004, Neurobiology of Disease.

[63]  R. Anwyl,et al.  Block of Long-Term Potentiation by Naturally Secreted and Synthetic Amyloid β-Peptide in Hippocampal Slices Is Mediated via Activation of the Kinases c-Jun N-Terminal Kinase, Cyclin-Dependent Kinase 5, and p38 Mitogen-Activated Protein Kinase as well as Metabotropic Glutamate Receptor Type 5 , 2004, The Journal of Neuroscience.

[64]  R. Nitsch,et al.  β-Amyloid Induces Paired Helical Filament-like Tau Filaments in Tissue Culture* , 2003, Journal of Biological Chemistry.

[65]  T. Arendt Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the ‘Dr. Jekyll and Mr. Hyde concept’ of Alzheimer’s disease or the yin and yang of neuroplasticity , 2003, Progress in Neurobiology.

[66]  R. Nitsch,et al.  Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. , 2003, The American journal of pathology.

[67]  X. Roucou,et al.  p75 Neurotrophin Receptor Protects Primary Cultures of Human Neurons against Extracellular Amyloid β Peptide Cytotoxicity , 2003, The Journal of Neuroscience.

[68]  M. Lynch,et al.  Activation of the c-Jun N-terminal Kinase Signaling Cascade Mediates the Effect of Amyloid-β on Long Term Potentiation and Cell Death in Hippocampus , 2003, Journal of Biological Chemistry.

[69]  L. Murri,et al.  Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.

[70]  J. Regula,et al.  Reconstitution of γ-secretase activity , 2003, Nature Cell Biology.

[71]  M. Robin,et al.  Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells , 2003, The Journal of cell biology.

[72]  G. Krafft,et al.  In Vitro Characterization of Conditions for Amyloid-β Peptide Oligomerization and Fibrillogenesis* , 2003, The Journal of Biological Chemistry.

[73]  D. Selkoe Alzheimer's Disease Is a Synaptic Failure , 2002, Science.

[74]  Jürgen Götz,et al.  Glial cells under physiologic and pathologic conditions. , 2002, Archives of neurology.

[75]  A. Delacourte,et al.  Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease , 2002, Neurology.

[76]  G. Lynch,et al.  Uptake and pathogenic effects of amyloid beta peptide 1–42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists , 2002, Neuroscience.

[77]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[79]  G. Perini,et al.  Role of p75 Neurotrophin Receptor in the Neurotoxicity by β-amyloid Peptides and Synergistic Effect of Inflammatory Cytokines , 2002, The Journal of experimental medicine.

[80]  R. Lal,et al.  Amyloid β protein forms ion channels: implications for Alzheimer's disease pathophysiology , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  R. Nitsch,et al.  Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. , 2001, The Journal of biological chemistry.

[82]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[83]  R. Nitsch,et al.  Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice , 2001, Neuroreport.

[84]  Jürgen Götz,et al.  Tau and transgenic animal models , 2001, Brain Research Reviews.

[85]  R. Nitsch,et al.  Oligodendroglial tau filament formation in transgenic mice expressing G272V tau , 2001, The European journal of neuroscience.

[86]  C. Masters,et al.  Sublethal Concentrations of Prion Peptide PrP106–126 or the Amyloid Beta Peptide of Alzheimer's Disease Activates Expression of Proapoptotic Markers in Primary Cortical Neurons , 2001, Neurobiology of Disease.

[87]  D. Neary,et al.  Distinct behavioural profiles in frontotemporal dementia and semantic dementia , 2001, Journal of neurology, neurosurgery, and psychiatry.

[88]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[89]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[90]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[91]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[92]  R. Lal,et al.  Fresh and globular amyloid β protein (1–42) induces rapid cellular degeneration: evidence for AβP channel‐mediated cellular toxicity , 2000 .

[93]  R. A. Crowther,et al.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.

[94]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[95]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[96]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[97]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[98]  B. Sommer,et al.  Association of microglia with amyloid plaques in brains of APP23 transgenic mice. , 1999, The American journal of pathology.

[99]  Carl W. Cotman,et al.  β-Amyloid Induces Local Neurite Degeneration in Cultured Hippocampal Neurons: Evidence for Neuritic Apoptosis , 1998, Neurobiology of Disease.

[100]  H. Band,et al.  Tau interacts with src-family non-receptor tyrosine kinases. , 1998, Journal of cell science.

[101]  Christian Hölscher,et al.  Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium Homeostasis , 1998, Neurobiology of Disease.

[102]  A Klug,et al.  Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[103]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[104]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[105]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[106]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[107]  G. Jicha,et al.  Alz‐50 and MC‐1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau , 1997, Journal of neuroscience research.

[108]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[109]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[110]  E. Rojas,et al.  Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity , 1995, Cellular and Molecular Neurobiology.

[111]  H. Braak,et al.  Staging of alzheimer's disease-related neurofibrillary changes , 1995, Neurobiology of Aging.

[112]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[113]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[114]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[115]  E. Rojas,et al.  Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[116]  Carl W. Cotman,et al.  In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.

[117]  C. Cotman,et al.  Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. , 1991, European journal of pharmacology.

[118]  D. Kirschner,et al.  Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. , 1990, Science.

[119]  J. Walker,et al.  Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[120]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[121]  G. Glenner,et al.  Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein , 1984 .

[122]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[123]  N. Schonrock,et al.  Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? , 2008, Journal of Alzheimer's disease : JAD.

[124]  R. Cappai,et al.  Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. , 2008, Neurochemical research.

[125]  Chunyu Wang,et al.  Abeta40 protects non-toxic Abeta42 monomer from aggregation. , 2007, Journal of molecular biology.

[126]  M. Staufenbiel,et al.  Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. , 2007, The American journal of pathology.

[127]  M. Asunción Morán,et al.  Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. , 2007, Journal of Alzheimer's disease : JAD.

[128]  C. Masters,et al.  Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. , 2006, Journal of molecular biology.

[129]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[130]  P. Keller,et al.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. , 2005, Journal of neurochemistry.

[131]  X. Chen,et al.  Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[132]  W. K. Cullen,et al.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. , 2005, Nature medicine.

[133]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[134]  P. Greengard,et al.  Regulation of NMDA receptor trafficking by amyloid-beta. , 2005, Nature neuroscience.

[135]  J. Götz,et al.  Different tau epitopes define Abeta42-mediated tau insolubility. , 2005, Biochemical and Biophysical Research Communications - BBRC.

[136]  B. Penke,et al.  Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. , 2004, Journal of peptide science : an official publication of the European Peptide Society.

[137]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[138]  R. Deane,et al.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. , 2004, Neuron.

[139]  J. Regula,et al.  Reconstitution of gamma-secretase activity. , 2003, Nature cell biology.

[140]  J. Trojanowski,et al.  Neurodegenerative tauopathies. , 2001, Annual review of neuroscience.

[141]  D. Small,et al.  Alzheimer's disease and Abeta toxicity: from top to bottom. , 2001, Nature reviews. Neuroscience.

[142]  P. S. St George-Hyslop,et al.  A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. , 2000, Nature.

[143]  H. Lin,et al.  Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[144]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[145]  A. Schmidt,et al.  RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. , 1996, Nature.

[146]  C. Cotman,et al.  In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. , 1991, Brain research.

[147]  G. V. Van Hoesen,et al.  The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. , 1991, Cerebral cortex.

[148]  G. Glenner,et al.  Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. , 1984, Biochemical and biophysical research communications.

[149]  N. Iwata,et al.  Neuropsychiatric Disease and Treatment , 2022 .